Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Summit Therapeutics (SMMT) over the last 8 years, with Q3 2025 value amounting to $856000.0.

  • Summit Therapeutics' Gains from Investment Securities changed N/A to $856000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 740.04%. This contributed to the annual value of $4.2 million for FY2024, which is 68.32% down from last year.
  • Per Summit Therapeutics' latest filing, its Gains from Investment Securities stood at $856000.0 for Q3 2025.
  • In the past 5 years, Summit Therapeutics' Gains from Investment Securities ranged from a high of $4.2 million in Q2 2023 and a low of $104000.0 during Q4 2022
  • Its 5-year average for Gains from Investment Securities is $1.9 million, with a median of $1.3 million in 2021.
  • In the last 5 years, Summit Therapeutics' Gains from Investment Securities surged by 12660000.0% in 2021 and then tumbled by 9177.87% in 2022.
  • Over the past 5 years, Summit Therapeutics' Gains from Investment Securities (Quarter) stood at $1.3 million in 2021, then crashed by 91.78% to $104000.0 in 2022, then skyrocketed by 3981.73% to $4.2 million in 2023, then fell by 0.68% to $4.2 million in 2024, then plummeted by 79.7% to $856000.0 in 2025.
  • Its Gains from Investment Securities was $856000.0 in Q3 2025, compared to $2.3 million in Q2 2025 and $1.4 million in Q1 2025.